ANNEX I. SUMMARY OF PRODUCT CHARACTERISTICS. 1 INTEGRILIN is indicated for the prevention of early myocardial infarction in adults presenting. Package leaflet: Information for the patient. Integrilin mg/ml solution for infusion eptifibatide. Read all of this leaflet carefully before you start using this. 1. Package leaflet: Information for the patient. Eptifibatide Accord 2 mg/ml solution for injection eptifibatide. Read all of this leaflet carefully before you start using.
|Published (Last):||6 November 2013|
|PDF File Size:||5.90 Mb|
|ePub File Size:||12.89 Mb|
|Price:||Free* [*Free Regsitration Required]|
The most common bleeding complications were related to cardiac revascularization CABG-related or femoral artery access site bleeding. A total of patients underwent PCI within 72 hours after randomization, in which case they received intravenous heparin to maintain an ACT of to seconds. Has been used as an adjunct to thrombolytic therapy e. Instruct patients to inform the doctor or healthcare provider about any medical conditions, medications, and allergies.
Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Plasma elimination half-life is approximately 2. Not known whether eptifibatide is distributed into breast milk.
Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner.
Manufacturer recommends — mg initially and daily thereafter. Table 5 also shows the incidence of the components of the primary endpoint, death whether or not preceded by an MI and new MI in surviving patients at 30 days. Molecular basis of platelet function. Denominator is based on patients for whom data are available.
The structural formula is:.
None of these patients experienced an intracranial bleed or other inetgrilin bleeding. These 16, patients had a mean age of 62 years range: The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Plasma elimination half-life is approximately 2. Drug Interaction Comments Anticoagulants, oral Potential increased risk of bleeding 1 Use with caution 1 Dipyridamole Potential increased risk of bleeding 1 Use with caution 1 Enoxaparin Pharmacokinetic or pharmacodynamic e.
Lntegrilin benefits and risks of coronary intervention—-balancing the equation. Most major bleeding associated with Integrilin has been at the arterial access site for cardiac catheterization or from the gastrointestinal or genitourinary tract.
If a patient packgae low platelet counts is receiving Eptifibatide Injection, their platelet count should be monitored closely. Unstable angina in the US: Instruct patients to inform the doctor or healthcare provider about any medical conditions, medications, and allergies.
Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet. Vials may be transferred to room ineert storage apckage for a period not to exceed 2 months. As shown in Table 9, the treatment effect of eptifibatide seen at 48 hours and 30 days appeared preserved at 6 months and 1 year.
Heparin in acute coronary disease-requiem for a heavyweight? This difference may be a true treatment difference, the effect of other differences in these subgroups, or a statistical anomaly.
Integirlin any case, both heparin and eptifibatide should be discontinued and ibtegrilin hemostasis should be achieved at least 2 to 4 hours before hospital discharge.
To view content sources and attributions, please refer to our editorial policy. Minimize the use of arterial and venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a “DISCARD BY” date 2 months from the transfer date or the labeled expiration date, whichever comes first.
Prior aspirin use predicts worse outcomes in patients with non-ST elevation acute coronary syndromes. Receptor Suppression Using Eptifibatide Therapy.
Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients.
The reduction in the incidence of endpoint events in patients receiving eptifibatide was evident early during treatment, and this reduction was maintained through at least 30 days see Figure 1.
Dilution Eptifibatide – Integrilin ® – GlobalRPH
Aspirin and Heparin Dosing Recommendations In the clinical trials that showed eptifibatide to be effective, most patients received concomitant insfrt and heparin. Patients Abrupt Closure 65 5. FDA alerts for all medications. Oropharyngeal primarily gingivalgenitourinary, gastrointestinal, and retroperitoneal bleeding were also seen more commonly in Integrilin-treated patients compared to placebo-treated patients.
Care should be taken to center the spike within the circle on the stopper top. A minimum of 12 hours of infusion is recommended.